GlassScriptPhysician profile
Rikin Shah
NPI 1649560012
$85,976.15
in general payments reported to CMS, 2019-2025
8 companies · $27K in 2025
The $27K reported for 2025 was more than what 93% of Pediatric Hematology-Oncology providers received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $153 · 2020: $138 · 2021: $136 · 2022: $19K · 2023: $29K · 2024: $11K · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $45K · Travel and Lodging: $14K · Consulting Fee: $6,022 · Food and Beverage: $1,492 · Education: $156.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $45,342.50 |
| Travel and Lodging | $13,834.42 |
| Consulting Fee | $6,022.00 |
| Food and Beverage | $1,492.43 |
| Education | $155.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $85,331.48 | 2021-2025 | |
| Genetix Biotherapeutics INC | $218.06 | 2025 | Lyfgenia |
| Servier Pharmaceuticals LLC | $133.37 | 2019 | |
| Novartis Pharmaceuticals Corporation | $104.95 | 2020 | |
| Adaptive Biotechnologies Corporation | $97.26 | 2022 | |
| Incyte Corporation | $62.22 | 2019-2021 | |
| Celgene Corporation | $15.48 | 2021 | |
| Jazz Pharmaceuticals INC. | $13.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rikin Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.